Overview

This trial is active, not recruiting.

Condition wet amd
Sponsor West Coast Retina Medical Group, Inc.
Collaborator Genentech
Start date April 2011
End date April 2012
Trial size 40 participants
Trial identifier NCT01310686, FVF4990s

Summary

To obtain a genotypic analysis of patients with chronic exudative age-related macular degeneration noted to have subretinal or intraretinal edema despite continuous monthly Anti-VEGF therapy.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective retrospective
Arm

Primary Outcomes

Measure
Genetic analysis of patients with chronic wet age-related macular degeneration despite continuous anti-VEGF treatment
time frame: This is a one time only blood draw.

Secondary Outcomes

Measure
To evaluate demographic and clinical characteristics in patients treated with anti-VEGF therapy who fail to respond completely.
time frame: This is a one time only blood draw and assessment of clinical characteristics.

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Ability to provide written informed consent for participation in this study - Subjects diagnoses of neovascular AMD who are on a monthly anti-VEGF regimen (have had >10 or more ranibizumab and/or bevacizumab injections within the last year) and who still have intra-retinal or subretinal fluid as confirmed by the Investigator Exclusion Criteria: - Subjects with a Pigment Epithelial Detachment Exclusively - Subjects with Serous Pigment Epithelial Detachments - Subjects with history of the following: idiopathic polypoidal choroidal vasculopathy - pathologic degenerative myopia - central serous chorioretinopathy - familial drusen - adult onset foveal pattern dystrophy

Additional Information

Official title Genotypic Evaluation of Chronic Exudative Macular Degeneration Despite Monthly Anti-Vascular Endothelial Growth Factor (VEGF) Therapy
Trial information was received from ClinicalTrials.gov and was last updated in February 2012.
Information provided to ClinicalTrials.gov by West Coast Retina Medical Group, Inc..